Lack of RDP Unlikely Threat to Biogen’s Tecfidera EU Patents

By Asthika Goonewardene, Bloomberg Industries, and Aude Gerspacher, Bloomberg Law


The EU regulatory body’s denial of regulatory data protection (RDP) does not impact the strength of Biogen’s European patents, Aude Gerspacher, a Bloomberg Law writer and editor with more than 10 years’ experience as a patent attorney said in a call with Bloomberg Industries’ Asthika Goonewardene.


Whether or not Biogen gets data exclusivity in Europe has no bearing on the strength of their European patents, she said.



Bloomberg BRIEF Newsletters